NEW YORK, Jan. 04, 2018 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against INC Research Holdings, Inc. ("INC Research" or the "Company") (NASDAQ:INCR) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired INC Research securities between May 10, 2017, and November 9, 2017, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: http://www.bgandg.com/incr.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.
On August 1, 2017, INC Research and inVentiv Health, Inc. (“inVentiv Health”) announced the completion of a merger between the two companies. On November 9, 2017, INC Research reported its first financial results after combining with inVentiv Health. The Company’s combined results were negatively impacted by merger-related expenses, an impairment charge and increased amortization expenses. Following this news, INC Research stock dropped $16.35 per share, or 28.43%, to close at $41.15 on November 9, 2017. The stock price continued to drop over the next three trading sessions, closing on November 14, 2017 at $34.35 per share, a total decline of $23.15 per share, or 40.3%.
The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that: (1) the Merger was not providing the benefit that Defendants stated it would; (2) inVentiv was underperforming; (3) consequently, the Company’s 2017 financial performance would be negatively impacted; and (4) as a result of the foregoing, Defendants’ statements about INCR’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/incr or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in INC Research you have until February 2, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]


Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves
FTC Questions Apple News Over Alleged Bias Against Conservative Media
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss
How Marco Pharma International Preserves German Homeopathic Traditions in America
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 



